Viking Therapeutics, Inc. (VKTX): Total Liabilities
$76.67M
As of 2025-12-31
$113.58M
As of 2026-06-30
+48.9%
3-year compound annual growth
+44.5%
5-year compound annual growth
+27.6%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $76.67M | +173.4% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $28.04M | +39.7% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $20.07M | -13.5% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $23.21M | +164.4% | 2024-02-07, Balance as of period end |
| 2021-12-31 | $8.78M | -27.8% | 2023-02-10, Balance as of period end |
| 2020-12-31 | $12.16M | +70.4% | 2022-02-09, Balance as of period end |
| 2019-12-31 | $7.14M | +56.4% | 2021-02-17, Balance as of period end |
| 2018-12-31 | $4.56M | -47.3% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $8.66M | +33.3% | 2019-03-13, Balance as of period end |
| 2016-12-31 | $6.49M | -3.3% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $6.71M | -73.3% | 2017-03-21, Balance as of period end |
| 2014-12-31 | $25.17M | n/a | 2016-03-08, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $76.67M | +173.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare VKTX, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗